HOWL News
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
Zacks
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
Zacks
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon closing of the proposed transaction, Werewolf shareholders are expected to own approximately 6.8% of the combined company.Halper Sadeh...
Business Wire
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC $HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire NEW YORK, Aug. 23, 2026 NEW YORK, Aug. 23, 2026 /PRNewswire...
PR Newswire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers
Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million.
Jupiter Neurosciences (NASDAQ:JUNS)read more...
Benzinga
Gold Moves Higher; US Composite PMI Surges In August
Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.read more...
Benzinga
65,000 Patients a Year, Zero Approved Drugs, One Phase 3 Trial
Biotech mergers can completely remake small public companies overnight, particularly when a transaction brings together a late-stage clinical asset, institutional capital and a clear regulatory path. Add an orphan disease with no FDA-approved drug therapy, and investors suddenly have a very different company to value than the one that existed the day before.Shares of Werewolf Therapeutics, Inc. (Nasdaq: HOWL) are soaring Friday after the immuno-oncology company announced a definitive all-stock merger with privately held Ambros Therapeutics alongside an oversubscribed $150 million private ...
AllPennyStocks.com
65,000 Patients a Year, Zero Approved Drugs, One Phase 3 Trial
Biotech mergers can completely remake small public companies overnight, particularly when a transaction brings together a late-stage clinical asset, institutional capital and a clear regulatory path. Add an orphan disease with no FDA-approved drug therapy, and investors suddenly have a very different company to value than the one that existed the day before.Shares of Werewolf Therapeutics, Inc. (Nasdaq: HOWL) are soaring Friday after the immuno-oncology company announced a definitive all-stock merger with privately held Ambros Therapeutics alongside an oversubscribed $150 million private ...
AllPennyStocks.com
Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.read more...
Benzinga